SK bioscience bags fresh backing to accelerate fight against respiratory disease

RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute

LANXESS marks 40 yrs of animal disease defense 'Virkon S'

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats

Bioxytran reports 90% day-5 viral clearance in COVID-19 trial at highest dose of ProLectin-M

Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile

Moderna wins EU backing for world’s first combined flu-COVID shot

The decision marks a pivotal moment for the Massachusetts-based biotech giant

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly

The data highlights its RSV vaccine cuts hospitalizations in older adults

Beyfortus cuts RSV hospitalizations across two seasons in landmark study

The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons

Centivax launches first human trial of universal flu vaccine

Aicuris’ Pritelivir delivers Phase 3 win in hard-to-treat herpes patients

The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing